Manz M, Steinbeck G, Nitsch J, Lüderitz B
Br Heart J. 1983 Mar;49(3):222-8. doi: 10.1136/hrt.49.3.222.
Oral antiarrhythmic treatment with mexiletine and disopyramide was evaluated in 34 patients with recurrent sustained ventricular tachycardias by programmed ventricular stimulation, except in a few instances where spontaneous attacks occurred under therapy. Coronary heart disease was present in 17 patients, cardiomyopathy in 11, myocarditis in five, and mitral valve prolapse in one. Complete suppression of ventricular tachycardia was observed in three of 30 patients under mexiletine and in one of 25 patients under disopyramide. Disopyramide slowed the rate of the ventricular tachycardia considerably, while mexiletine had no such influence. For a mean of 24 months, 19 patients were maintained on either substance. Complete suppression of ventricular tachycardia during programmed stimulation predicted freedom from recurrences. Ventricular tachycardias recurred less frequently and at a slower rate in the other patients, but 31% have died. This study shows that complete suppression of ventricular tachycardia by mexiletine or disopyramide can be achieved only in a minority of patients with previously drug-resistant tachycardias.
除少数在治疗期间发生自发发作的情况外,对34例复发性持续性室性心动过速患者进行了美西律和丙吡胺的口服抗心律失常治疗评估,通过程控心室刺激进行评估。17例患者患有冠心病,11例患有心肌病,5例患有心肌炎,1例患有二尖瓣脱垂。在接受美西律治疗的30例患者中有3例、接受丙吡胺治疗的25例患者中有1例观察到室性心动过速完全被抑制。丙吡胺显著减慢了室性心动过速的速率,而美西律没有这种作用。19例患者平均使用其中一种药物维持治疗24个月。程控刺激期间室性心动过速的完全抑制预示着无复发。其他患者室性心动过速复发频率较低且速率较慢,但31%的患者已经死亡。这项研究表明,美西律或丙吡胺仅能在少数先前对药物耐药的心动过速患者中实现室性心动过速的完全抑制。